Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Phentermine HCL Blue Speckled tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0025-10 D-1532-2020
Class II · Moderate risk

Phentermine HCL Blue/White Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0029-10 D-1529-2020
Class II · Moderate risk

Phentermine HCL Blue/Clear capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0028-10 D-1528-2020
Class II · Moderate risk

Phentermine HCL Yellow Caps 30mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 51224-0202-70 D-1527-2020
Class II · Moderate risk

Phentermine HCL GrayYellow capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 51224-0203-70 D-1526-2020
Class II · Moderate risk

Phentermine 15mg grey/Yellow Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 11534-0157-03 D-1525-2020
Class II · Moderate risk

Phentermine HCL Gray/Yellow capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0026-10 D-1524-2020
Class II · Moderate risk

Phendimetrazine Brown/Clear Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 69543-0409-11 D-1523-2020
Class II · Moderate risk

Phendimetrazine Yellow Tabs 35mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 69543-0410-11 D-1522-2020
Class II · Moderate risk

Phendimetrazine Yellow Tabs 35mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 0702-0077-10 D-1521-2020
Class II · Moderate risk

Topiramate 25mg Tabs White/round tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 47335-0707-13 D-1520-2020
Class II · Moderate risk

Thyroid Neutral Tabs 2 gr

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 64727-3308-02 D-1519-2020
Class II · Moderate risk

Thyroid 1 Gr tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 64727-3300-01 D-1518-2020